Research Topics
Species | Amy FultonSummaryAffiliation: University of Maryland Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Promoter methylation regulates cyclooxygenase expression in breast cancerXinrong Ma
Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA
Breast Cancer Res 6:R316-21. 2004..Aberrant CpG island methylation, and subsequent silencing of the COX-2 promoter, has been observed in human cancer cell lines and in some human tumors of the gastrointestinal tract...- The chemokine receptors CXCR4 and CXCR3 in cancerAmy M Fulton
University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
Curr Oncol Rep 11:125-31. 2009..It also describes recent therapeutic approaches that target these receptors or their ligands... - Targeting prostaglandin E EP receptors to inhibit metastasisAmy M Fulton
Department of Pathology and Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
Cancer Res 66:9794-7. 2006..These initial results indicate that selective targeting of individual EP receptors should be investigated as an approach to exploit the high COX-2 activity in many epithelial malignancies... - CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine modelXinrong Ma
University of Maryland Greenebaum Cancer Center, Department of Pathology, School of Medicine, 9th Floor, 655 West Baltimore Street, Baltimore, MD 21201, USA
Mol Cancer Ther 8:490-8. 2009..These studies support the continued examination of CXCR3 as a potential therapeutic target in patients with breast cancer... - Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4Dawn Holt
Department of Pathology, School of Medicine, University of Maryland, Baltimore, USA
Cancer Immunol Immunother 60:1577-86. 2011.... - Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancerNamita Kundu
Department of Pathology, University of Maryland School of Medicine, 10 South Pine Street, Baltimore, MD 21201, USA
Cancer Res 62:2343-6. 2002..Growth of a second cell line, which does not express COX-2 in vivo, is also reduced by celecoxib, implicating both COX-dependent and COX-independent mechanisms... - Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancerTonya C Walser
Department of Pathology, University of Maryland School of Medicine, 10 South Pine Street, Baltimore, MD 21201, USA
Cancer Res 66:7701-7. 2006..These studies also indicate for the first time that a small molecular weight antagonist of CXCR3 has the potential to inhibit tumor metastasis... - Prospects of controlling breast cancer metastasis by immune interventionAmy Fulton
University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
Breast Dis 26:115-27. 2006..To enhance tumor infiltration by immune effectors, the role of CXCL9 is discussed. The complex nature of tumor metastasis necessitates a comprehensive approach to achieve successful immune intervention... - Prostaglandin E2 EP receptors as therapeutic targets in breast cancerJocelyn Reader
University of Maryland Marlene and Stewart Greenebaum Cancer Center, 655 W Baltimore, St Baltimore, MD 21201, USA
Cancer Metastasis Rev 30:449-63. 2011..As knowledge concerning the role of EP receptors in cancer grows, so does the potential for exploiting EP receptors as therapeutic targets for the treatment or prevention of cancer and cancer metastasis... - Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasisXinrong Ma
Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
Cancer Res 66:2923-7. 2006..These studies support the hypothesis that EP receptor antagonists may be an alternative approach to the use of COX inhibitors to prevent tumor metastasis... - Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK functionNamita Kundu
Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Breast Cancer Res Treat 117:235-42. 2009.... - Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cellsPratima Sinha
Department of Biological Sciences, University of Maryland Baltimore County, University of Maryland, Baltimore, Maryland 21250, USA
Cancer Res 67:4507-13. 2007.... - Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine modelTonya C Walser
Department of Pathology, University of Maryland School of Medicine, 10 South Pine Street, Baltimore, MD 21201, USA
J Immunother 30:490-8. 2007..These studies also implicate host NK cells as an additional effector cell critical for Mig-mediated control of metastasis... - Cyclooxygenase inhibitors modulate NK activities that control metastatic diseaseNamita Kundu
Department of Pathology, University of Maryland, 10 S. Pine St, Baltimore, MD 21201, USA
Cancer Immunol Immunother 54:981-7. 2005..Taken together, these findings are consistent with a mechanism not previously described, whereby COX inhibitors may relieve MHC-mediated inhibition of NK cytotoxicity leading to recognition and lysis of metastatic tumor cells... - The role of chemokines in the biology and therapy of breast cancerTonya C Walser
Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Breast Dis 20:137-43. 2004..The roles of other chemokine receptors and ligands are under active investigation... - Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycleNamita Kundu
Department of Pathology, University of Maryland School of Medicine, Baltimore 21201, USA
Breast Cancer Res Treat 76:57-64. 2002..Thus, mammary tumor cells are growth restricted by Cox inhibitors. These effects are associated with changes in ceramide levels and a block in cell cycle progression...
Research Grants
- Cyclooxygenase Modulators of Immune Function in Breast CancerAmy Fulton; Fiscal Year: 2009..Immune-based therapies are attractive alternatives to existing therapies and the proposed studies may identify a strategy that would boost both innate and adaptive arms of the antitumor immune response. ..
- Cyclooxygenase Modulators of Immune Function in Breast CancerAmy Fulton; Fiscal Year: 2010..Immune-based therapies are attractive alternatives to existing therapies and the proposed studies may identify a strategy that would boost both innate and adaptive arms of the antitumor immune response. ..
- INTERLEUKIN 10 AND BREAST CANCER THERAPYAmy Fulton; Fiscal Year: 2006..Specific receptor for these chemokines, CXCR3, has been reported on tumor-infiltrating lymphocytes and NK cells. We have detected CXCR3 on mammary tumor cells. Specific Aim 4 will determine the role of CXCR3 in tumor behavior. ..
- INTERLEUKIN 10 AND BREAST CANCER THERAPYAmy Fulton; Fiscal Year: 2001..The effect of IL-10 overexpression on the growth and metastasis of human breast cancer cells will be determined. The role of mig-1 and gbp-1 will be examined in human tumors. ..
- Cyclooxygenase Modulators of Immune Function in Breast CancerAmy Fulton; Fiscal Year: 2010..Immune-based therapies are attractive alternatives to existing therapies and the proposed studies may identify a strategy that would boost both innate and adaptive arms of the antitumor immune response. ..